Psoriatic Arthritis Case Study

682 Words2 Pages

A review of the records reveals the member to be an adult female with a birth date of 07/30/1960. The member has a diagnosis of psoriatic arthritis. The member’s treating provider, Lisa Allen, MD recommended the member continue treatment with Otezla (Apremilast).

The carrier has denied coverage of treatment with Otezla (Apremilast) as not medically necessary. There is a letter from the carrier to the member dated 04/08/2016 which states in part:

“Based on a thorough review of the information provided, a determination was made to uphold the denial for coverage of Otezla. You requested a medication called Apremilast OtezlaTablets) to treat your psoriatic arthritis. This request for coverage of Apremilast OtezlaTablets) remains denied because according to the information provided to us you do not have a documented inadequate response or inability to tolerate a traditional DMARD and two preferred/formulary targeted immunomodulators, if available (e.g. Humira, Enbrel). This determination was based upon Capital BlueCross' Medical Policy Criteria regarding Medical Necessity Criteria for Pharmaceuticals: Biologic Disease Modifying Antirheumatic Drugs (DMARDS) RXCRIT-4. External case review by a board certified Rheumatologist was obtained, who concurred with …show more content…

Patient currently takes Sulfasalazine and Ibuprofen, but still with only partial control-should have better psoriatic control. Patient has also tried Plaquenil (allergic), Prednisone, Celebrex (allergic), Ultram, Meloxicam, Flexeril, and Depo-Medrol. Patient cannot take Methtrexate or Arava due to alcohol use. Patient has fear of using Humira and Enbrel due to having to give self-injections and all the potential side effects that she has read about; however, patient disease is not controlled and we need to get her on a medication that will control her disease that she will actually take. Patient still with joint pain and swelling in both

More about Psoriatic Arthritis Case Study

Open Document